Health & WellnessGlobal (GL)
stat+: eli lilly’s zepbound combined with amylin drug led to significant weight loss in mid-stage trial
First reported: 21h agoUpdated: 21h ago1 source covering
⚠️ Content Notice
This story relates to health or medical topics. HeadlineSift's AI-generated summaries are for informational purposes only and do not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional for medical decisions.
AI analysis is pending for this story. Check back soon.
Sources & Attribution
STAT News
861 article
Original Articles (1)
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
Read original →STAT News·Elaine Chen·Wednesday, September 30, 2026 2:15 PM